Anne M. van der Leun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne M. van der Leun has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Ton N. M. Schumacher
Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
43 shared publications - Daniela S. Thommen
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands
42 shared publications - Charlotte L. Zuur
Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands
38 shared publications - John B. A. G. Haanen
The Netherlands Cancer Institute
38 shared publications - Joris L. Vos
Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
38 shared publications - Mercedes Machuca-Ostos
Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 1
38 shared publications
Latest Publications
- Open Access
Reinvigoration of translational activity in dysfunctional T cells initiates the early intratumoral response to PD-1 blockade
T cells are key effectors of antitumor responses elicited by PD-1 blockade. However, it remains elusive by which mechanism(s) PD-1 blockade initiates T cell-driven antitumor immunity in cancer tissues. Here, we dissect early T cell reactivation upon anti-PD-1 in patient-derived tumor fragments. Using bispecific antibodies to target anti-PD-1 to individual T cell subsets, we demonstrate that intratumoral CD8 + and CD4 + T cells can independently drive immune remodeling of the tumor microenvironment. The CD8 + and CD4 + T cells that respond to anti- PD-1 exhibit a shared dysfunctional gene program, characterized by tumor-reactivity, terminal exhaustion, effector capacity, and reduced translational activity. Notably, rather than acting through transcriptional rewiring, anti-PD-1 reinvigorates dysfunctional T cells by overcoming this translational barrier, resulting in restored effector function. Altogether, these results reveal dysfunctional T cells as initiators of early tissue responses to PD-1 blockade and identify a novel mode of their therapeutic reinvigoration through restoration of translational control. One Sentence Summary: Translational reactivation of tumor-residing dysfunctional T cells drives early intratumoral immune activity upon PD-1 blockade.
Open AccessReinvigoration of translational activity in dysfunctional T cells initiates the early intratumoral response to PD-1 blockade
T cells are key effectors of antitumor responses elicited by PD-1 blockade. However, it remains elusive by which mechanism(s) PD-1 blockade initiates T cell-driven antitumor immunity in cancer tissues. Here, we dissect early T cell reactivation upon anti-PD-1 in patient-derived tumor fragments. Using bispecific antibodies to target anti-PD-1 to individual T cell subsets, we demonstrate that intratumoral CD8 + and CD4 + T cells can independently drive immune remodeling of the tumor microenvironment. The CD8 + and CD4 + T cells that respond to anti- PD-1 exhibit a shared dysfunctional gene program, characterized by tumor-reactivity, terminal exhaustion, effector capacity, and reduced translational activity. Notably, rather than acting through transcriptional rewiring, anti-PD-1 reinvigorates dysfunctional T cells by overcoming this translational barrier, resulting in restored effector function. Altogether, these results reveal dysfunctional T cells as initiators of early tissue responses to PD-1 blockade and identify a novel mode of their therapeutic reinvigoration through restoration of translational control. One Sentence Summary: Translational reactivation of tumor-residing dysfunctional T cells drives early intratumoral immune activity upon PD-1 blockade.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
To dissect the effect of neoadjuvant PD-1 and CTLA4 blockade on intratumoral T cells in treatment-naive head and neck squamous cell carcinoma, we analyzed primary tumor immune infiltrates from responding and non-responding patients. At baseline, a higher ratio between active (4-1BB/OX-40+) and inactive regulatory CD4+ T cells was associated with immunotherapy response. Furthermore, upon therapy, this active Treg population showed a profound decrease in responding patients. In an analogous process, intratumoral dysfunctional CD8+ T cells displayed decreased expression of activity and dysfunction-related genes in responding patients, while in clinical non-responders NK cells showed an increased cytotoxic profile early upon treatment. These data reveal immunological changes in response to dual PD-1/CTLA4 blockade, including a parallel remodeling of presumed tumor-reactive Treg and CD8+ T cell compartments in responding patients, and indicate that the presence of activated Tregs at baseline may be associated with response.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
To dissect the effect of neoadjuvant PD-1 and CTLA4 blockade on intratumoral T cells in treatment-naive head and neck squamous cell carcinoma, we analyzed primary tumor immune infiltrates from responding and non-responding patients. At baseline, a higher ratio between active (4-1BB/OX-40+) and inactive regulatory CD4+ T cells was associated with immunotherapy response. Furthermore, upon therapy, this active Treg population showed a profound decrease in responding patients. In an analogous process, intratumoral dysfunctional CD8+ T cells displayed decreased expression of activity and dysfunction-related genes in responding patients, while in clinical non-responders NK cells showed an increased cytotoxic profile early upon treatment. These data reveal immunological changes in response to dual PD-1/CTLA4 blockade, including a parallel remodeling of presumed tumor-reactive Treg and CD8+ T cell compartments in responding patients, and indicate that the presence of activated Tregs at baseline may be associated with response.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Dual ICB-induced changes in dysfunctional CD8+ T cells of responding patients towards a less dysfunctional state.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Dual ICB-induced changes in dysfunctional CD8+ T cells of responding patients towards a less dysfunctional state.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
ICB-induced changes in immune cell state abundance and gene expression profiles.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
ICB-induced changes in immune cell state abundance and gene expression profiles.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Gene expression changes associated with response and resistance to ICB across cell states.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Gene expression changes associated with response and resistance to ICB across cell states.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S10 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Overlap between the Treg and dysfunctional CD8+ T cell trajectory signatures.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Overlap between the Treg and dysfunctional CD8+ T cell trajectory signatures.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Table S2 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Table S2 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Differentially expressed genes between TregTNFRSF9 versus TregGIMAP in pre-treatment samples.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Differentially expressed genes between TregTNFRSF9 versus TregGIMAP in pre-treatment samples.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Dual ICB-induced changes in activation state of Tregs.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Dual ICB-induced changes in activation state of Tregs.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Gene expression changes associated with response and resistance to ICB across cell states.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Gene expression changes associated with response and resistance to ICB across cell states.